MedTrace Logo

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

NCT02771509 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 275

Last updated 2021-07-15

No results posted yet for this study

Summary

The objective of the study is to assess the safety and efficacy of ANG-3777 in preventing AKI compared to placebo when administered to patients at risk for developing acute kidney injury (AKI) following cardiac surgical procedures involving cardiopulmonary bypass (CPB).

Conditions

Interventions

DRUG

ANG-3777

6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose

DRUG

Placebo

Normal saline

Sponsors & Collaborators

  • Everest Clinical Research

    collaborator UNKNOWN

  • CTI Clinical Trial and Consulting Services

    collaborator OTHER

  • Clinical Accelerator

    collaborator INDUSTRY

  • Angion Biomedica Corp

    lead INDUSTRY

Principal Investigators

  • John Neylan, MD · Angion Biomedica

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-24
Primary Completion
2021-08-31
Completion
2021-08-31
FDA Drug
Yes

Countries

  • United States
  • Brazil
  • Canada
  • Georgia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02771509 on ClinicalTrials.gov